Study of Oglemilast for the Treatment of Asthma

Forest Laboratories6 enrolled

Overview

The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Enrollment

Conditions

Asthma

Interventions

OglemilastDRUG

Oglemilast, 15mg oral administration, once per day and then dose-matched placebo

Placebo then OglemilastDRUG

Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Mild atopic asthma * Hyperreactivity to methacholine * Exhibit positive response to standard allergen skin prick test Exclusion Criteria: * Pulmonary disease other than asthma * Asthma exacerbation within 4 weeks * History of substance abuse * Active cardiac disease

Locations (1)

Forest Investigative Site

Los Angeles, California, United States

Outcomes

Primary Outcomes

To determine the effect of oglemilast in the prevention of bronchoconstriction after the administration of allergen, in comparison with placebo in patients with mild asthma

Time frame: From Baseline to Day 7

Secondary Outcomes

To evaluate the safety of oglemilast over 2 weeks as determined by adverse events,physical examinations, vital signs, electrocardiograms, and laboratory examinations

Time frame: From Baseline to Day 14

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.